Effects of single dose intranasal oxytocin on social cognition in schizophrenia
Abstract
Deficits in social cognition are common in schizophrenia and predict poor community functioning. Given the current limitations of psychosocial treatments and the lack of pharmacological treatments for social cognitive deficits, the development of novel therapeutic agents could greatly enhance functional recovery in schizophrenia. This study evaluated whether a single dose of intranasal oxytocin acutely improves social cognitive functioning in schizophrenia. Twenty-three male veterans with schizophrenia completed baseline assessments of social cognition that were divided into lower-level (facial affect perception, social perception, detection of lies) and higher-level (detection of sarcasm and deception, empathy) processes. One week later, patients received the same battery after being randomized to a single dose of 40 IU intranasal oxytocin or placebo. Though the groups did not differ significantly on the social cognition composite score, oxytocin improved performance for the higher-level social cognitive tasks (Cohen's d=1.0, p=0.045). Subjects were unable to accurately guess which treatment they had received. The improvements found in higher-level social cognition encourage further studies into the therapeutic potential of oxytocin in schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
OT's dampening effect on amygdala activity, regardless of emotional valence, may underlie reported improvements in social behavior and cognition after IN OT via these two levels of action.
“OT's dampening effect on amygdala activity, regardless of emotional valence, may underlie reported improvements in social behavior (Yatawara et al., 2015) and cognition (Davis et al., 2013; Guastella et al., 2010) after IN OT via these two levels of action.”
From Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial (2016) · cites this paper as Davis et al., 2013
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · see citing works
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247 · see citing works
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056 · see citing works
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833 · see citing works
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688 · see citing works
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356 · see citing works
Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.
Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.020 · Cited by 962 · see citing works
Oxytocin, vasopressin, and human social behavior
Heinrichs, M., von Dawans, B., & Domes, G. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.05.005 · Cited by 799 · see citing works
Sensitivity to Nonverbal Communication: The PONS Test
Rosenthal, R. (1979) · Cited by 777 · see citing works
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J. A., Buchanan, R. W., Dickerson, F., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D. A., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 758 · see citing works
Mcdonald (2003) · doi:10.1097/00001199-200305000-00001 · Cited by 657 · see citing works
Modulating social behavior with oxytocin: How does it work? What does it mean?
Churchland, P. S., & Winkielman, P. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.003 · Cited by 464 · see citing works
Oxytocin selectively improves empathic accuracy
Bartz, J. A., Zaki, J., Bolger, N., Hollander, E., Ludwig, N. N., Kolevzon, A., & Ochsner, K. N. (2010) · Psychological Science · doi:10.1177/0956797610383439 · Cited by 442 · see citing works
Schizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 412 · see citing works
On judging and being judged accurately in zero-acquaintance situations.
Ambady, N., Hallahan, M., & Rosenthal, R. (1995) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.69.3.518 · Cited by 367 · see citing works
A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research
MacDonald, E., Dadds, M. R., Brennan, J. L., Williams, K., Levy, F., & Cauchi, A. J. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.02.015 · Cited by 352 · cited 1× · see citing works
“In fact, no reliable side effects were noted in a review of 38 randomized controlled trials (MacDonald et al., 2011).”
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.039 · Cited by 308 · see citing works
Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.027 · Cited by 305 · see citing works
Mancuso, F., Horan, W. P., Kern, R. S., & Green, M. F. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.007 · Cited by 272 · see citing works
Self-citationMethamphetamine-Associated Psychosis
Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E., Carlo, G., & Bevins, R. A. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9288-1 · Cited by 231 · see citing works
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225 · see citing works
Generalized deficit in all core components of empathy in schizophrenia
Derntl, B., Finkelmeyer, A. E., Toygar, T., Hülsmann, A., Schneider, F. W., Falkenberg, D. I., & Habel, U. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.009 · Cited by 215 · see citing works
Goldman, M. B., Marlow-O’Connor, M., Torres, I. J., & Carter, C. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.019 · Cited by 211 · see citing works
Sharing secrets: oxytocin and trust in schizophrenia
Kéri, S., Kiss, I., & Kelemen, O. (2009) · Social Neuroscience · doi:10.1080/17470910802319710 · Cited by 167 · see citing works
Horan, W. P., Kern, R. S., Tripp, C., Hellemann, G., Wynn, J. K., Bell, M. D., Marder, S. R., & Green, M. F. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.01.015 · Cited by 156 · see citing works
Self-citationEmotion recognition and oxytocin in patients with schizophrenia
Averbeck, B. B., Bobin, T., Evans, S., & Shergill, S. S. (2011) · Psychological Medicine · doi:10.1017/s0033291711001413 · Cited by 144 · see citing works
Elevated salivary levels of oxytocin persist more than 7 h after intranasal administration
van IJzendoorn, M. H., Bhandari, R., van der Veen, R., Grewen, K. M., & Bakermans-Kranenburg, M. J. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00174 · Cited by 137 · see citing works
The MIRECC Version of the Global Assessment of Functioning Scale: Reliability and Validity
Niv, N., Cohen, A. N., Sullivan, G., & Young, A. S. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.4.529 · Cited by 114 · see citing works
Goldman, M. B., Gomes, A. M., Carter, C. S., & Lee, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2193-8 · Cited by 112 · see citing works
Ditzen, B., Nater, U. M., Schaer, M., La Marca, R., Bodenmann, G., Ehlert, U., & Heinrichs, M. (2013) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nss083 · Cited by 111 · see citing works
Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia
Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M. H., Hosseini, S. M. R., Tajdini, M., Ghaleiha, A., & Akhondzadeh, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0022-1 · Cited by 107 · see citing works
Update on the management of symptoms in schizophrenia: focus on amisulpride
Mortimer, A. M. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3949 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 354 · see citing works
Self-citationIntranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis
Keech, B., Crowe, S., & Hocking, D. R. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.09.022 · Cited by 145 · see citing works
Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia
Davis, M. C., Green, M. F., Lee, J., Horan, W. P., Senturk, D., Clarke, A. D., & Marder, S. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.68 · Cited by 149 · see citing works
Self-citationCentral Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition
Salameh, T. S., Bullock, K. M., Hujoel, I. A., Niehoff, M. L., Wolden‐Hanson, T., Kim, J., Morley, J. E., Farr, S. A., & Banks, W. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150307 · Cited by 134 · see citing works
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi-Nazarloo, H., Drogos, L. L., Hill, S. K., Ruocco, A. C., Keedy, S. K., Reilly, J. L., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu027 · Cited by 127 · see citing works
Social Disconnection in Schizophrenia and the General Community
Green, M. F., Horan, W. P., Lee, J., McCleery, A., Reddy, L. F., & Wynn, J. K. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx082 · Cited by 131 · see citing works
Self-citationOxytocin, vasopressin, and the motivational forces that drive social behaviors
Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129 · see citing works
Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., Scott, E. M., Naismith, S. L., Moore, L., Alvares, G. A., Redoblado Hodge, M. A., & Guastella, A. J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu094 · Cited by 119 · see citing works
Millan, M. J., & Bales, K. L. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.012 · Cited by 116 · see citing works
Oxytocin and social functioning
Jones, C., Barrera, I., Brothers, S., Ring, R., & Wahlestedt, C. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/cjones · Cited by 132 · see citing works
Oxytocin administration enhances controlled social cognition in patients with schizophrenia
Woolley, J. D., Chuang, B., Lam, O., Lai, W., O’Donovan, A., Rankin, K. P., Mathalon, D. H., & Vinogradov, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.024 · Cited by 116 · see citing works
Agile delivery of protein therapeutics to CNS
Yi, X., Manickam, D. S., Brynskikh, A. M., & Kabanov, A. V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.017 · Cited by 115 · see citing works
Quintana, D. S., Guastella, A. J., Westlye, L. T., & Andreassen, O. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.166 · Cited by 107 · see citing works
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110 · see citing works
Quintana, D. S., Westlye, L. T., Alnæs, D., Rustan, Ø. G., Kaufmann, T., Smerud, K. T., Mahmoud, R. A., Djupesland, P. G., & Andreassen, O. A. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.04.010 · Cited by 102 · see citing works
Treatment of social cognition in schizophrenia: Current status and future directions
Horan, W. P., & Green, M. F. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.013 · Cited by 102 · see citing works
Self-citationSocial cognitive interventions for people with schizophrenia: A systematic review
Tan, B., Lee, S.-A., & Lee, J. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.06.013 · Cited by 97 · see citing works
Self-citationThe Role of the Oxytocin System in Anxiety Disorders
Yoon, S., & Kim, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_7 · Cited by 95 · see citing works
Improving Current Treatments for Schizophrenia
Marić, N. P., Jovicic, M. J., Mihaljevic, M. M., & Miljević, Č. (2016) · Drug Development Research · doi:10.1002/ddr.21337 · Cited by 85 · see citing works
Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients
Jobst, A., Dehning, S., Ruf, S., Notz, T., Buchheim, A., Henning-Fast, K., Meißner, D., Meyer, S., Bondy, B., Müller, N., et al. (2014) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.20 · Cited by 89 · see citing works
Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward
Bradley, E., & Woolley, J. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.007 · Cited by 88 · see citing works
Gibson, C. M., Penn, D. L., Smedley, K. L., Leserman, J., Elliott, T., & Pedersen, C. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.009 · Cited by 88 · see citing works
The many faces of oxytocin: Implications for psychiatry
Zik, J. B., & Roberts, D. L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.048 · Cited by 85 · see citing works
Potential of Oxytocin in the Treatment of Schizophrenia
Shilling, P. D., & Feifel, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0315-x · Cited by 82 · see citing works
Bürkner, P., Williams, D. R., Simmons, T. C., & Woolley, J. D. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx053 · Cited by 80 · see citing works
Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment
Goh, K. K., Chen, C.-H., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042146 · Cited by 78 · see citing works
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 73 · see citing works
A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia
Guastella, A. J., Ward, P. B., Hickie, I. B., Shahrestani, S., Hodge, M. A., Scott, E. M., & Langdon, R. A. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.005 · Cited by 66 · see citing works
Fang, A., Hoge, E. A., Heinrichs, M., & Hofmann, S. G. (2014) · Clinical Psychological Science · doi:10.1177/2167702614527948 · Cited by 60 · see citing works
Reversal of social deficits by subchronic oxytocin in two autism mouse models
Teng, B. L., Nikolova, V. D., Riddick, N. V., Agster, K. L., Crowley, J. J., Baker, L. K., Koller, B. H., Pedersen, C. A., Jarstfer, M. B., & Moy, S. S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.025 · Cited by 62 · see citing works
Aydın, O., Lysaker, P. H., Balıkçı, K., Ünal‐Aydın, P., & Esen-Danacı, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.03.048 · Cited by 62 · see citing works
A Role for Oxytocin in the Etiology and Treatment of Schizophrenia
Rich, M. E., & Caldwell, H. K. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00090 · Cited by 55 · see citing works
Smith, M. J., Schroeder, M., Abram, S. V., Goldman, M. B., Parrish, T. B., Wang, X., Derntl, B., Habel, U., Jean Decety, A., Reilly, J. L., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu023 · Cited by 55 · see citing works
Jarskog, L. F., Pedersen, C. A., Johnson, J. L., Hamer, R. M., Rau, S. W., Elliott, T., & Penn, D. L. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.008 · Cited by 55 · see citing works
Strauss, G. P., Keller, W. R., Koenig, J. I., Gold, J. M., Ossenfort, K. L., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.023 · Cited by 54 · see citing works
Bartholomeusz, C. F., Ganella, E. P., Labuschagne, I., Bousman, C., & Pantelis, C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.007 · Cited by 54 · see citing works
Oxytocin and social cognition in affective and psychotic disorders
Pérez-Rodríguez, M. M., Mahon, K., Russo, M., Ungar, A. K., & Burdick, K. E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.012 · Cited by 52 · see citing works
Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia
Strauss, G. P., Keller, W. R., Koenig, J. I., Gold, J. M., Frost, K. H., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.034 · Cited by 51 · see citing works
Strauss, G. P., Chapman, H. C., Keller, W. R., Koenig, J. I., Gold, J. M., Carpenter, W. T., & Buchanan, R. W. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.02.017 · Cited by 49 · see citing works
Some markers of mirroring appear intact in schizophrenia: evidence from mu suppression
Horan, W. P., Pineda, J. A., Wynn, J. K., Iacoboni, M., & Green, M. F. (2014) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-013-0245-8 · Cited by 47 · see citing works
Quintana, D. S., & Woolley, J. D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.021 · Cited by 46 · see citing works
Strauss, G. P., Keller, W. R., Koenig, J. I., Sullivan, S. K., Gold, J. M., & Buchanan, R. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.022 · Cited by 46 · see citing works
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
Aly, A. E.-E., & Waszczak, B. L. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1069815 · Cited by 45 · see citing works
Bose, M., Quipildor, G. F., Ehrlich, M. E., & Salton, S. R. (2022) · Cells · doi:10.3390/cells11223629 · Cited by 44 · see citing works
Do we need oxytocin to treat schizophrenia? A randomized clinical trial
Dagani, J., Sisti, D., Abelli, M., Paolo, L. D., Pini, S., Raimondi, S., Rocchi, M., Saviotti, F. M., Scocco, P., Totaro, S., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.011 · Cited by 41 · see citing works
Intranasal Oxytocin and Vasopressin Modulate Divergent Brainwide Functional Substrates
Galbusera, A., Felice, A. D., Girardi, S., Bassetto, G., Maschietto, M., Nishimori, K., Chini, B., Papaleo, F., Vassanelli, S., & Gozzi, A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.283 · Cited by 38 · see citing works
Buchanan, R. W., Kelly, D. L., Weiner, E., Gold, J. M., Strauss, G. P., Koola, M. M., McMahon, R. P., & Carpenter, W. T. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000720 · Cited by 40 · see citing works
Sabé, M., Zhao, N., Crippa, A., Strauss, G. P., & Kaiser, S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab020 · Cited by 40 · see citing works
Kumar, J., Vӧllm, B., & Palaniyappan, L. K. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu051 · Cited by 38 · see citing works
An IRT Analysis of the Reading the Mind in the Eyes Test
Black, J. E. (2018) · Journal of Personality Assessment · doi:10.1080/00223891.2018.1447946 · Cited by 38 · see citing works
Win‐Shwe, T., Kyi‐Tha‐Thu, C., Moe, Y., Fujitani, Y., Tsukahara, S., & Hirano, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00524 · Cited by 37 · see citing works
Studying the neurobiology of human social interaction: Making the case for ecological validity
Hogenelst, K., Schoevers, R. A., & Rot, M. A. H. (2015) · Social Neuroscience · doi:10.1080/17470919.2014.994786 · Cited by 36 · see citing works
Gumley, A. I., Braehler, C., & MacBeth, A. M. (2014) · British Journal of Clinical Psychology · doi:10.1111/bjc.12041 · Cited by 34 · see citing works
RetractedQuintana, D. S., Westlye, L. T., Alnæs, D., Kaufmann, T., Mahmoud, R. A., Smerud, K. T., Djupesland, P. G., & Andreassen, O. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0241-3 · Cited by 33 · see citing works
Attenuation of Oxytocin and Serotonin 2A Receptor Signaling through Novel Heteroreceptor Formation
Chruścicka, B., Fitzsimons, S. E. W., Borroto‐Escuela, D. O., Druelle, C. M., Stamou, P., Nally, K., Dinan, T. G., Cryan, J. F., Fuxé, K., & Schellekens, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00665 · Cited by 34 · see citing works
Oxytocin and parenting behavior among impoverished mothers with low vs. high early life stress
Julian, M. M., Rosenblum, K. L., Doom, J. R., Leung, C. Y. Y., Lumeng, J. C., Cruz, M. G., Vázquez, D. M., & Miller, A. L. (2017) · Archives of Women s Mental Health · doi:10.1007/s00737-017-0798-6 · Cited by 34 · see citing works
Green, M. F., Lee, J., & Ochsner, K. N. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt131 · Cited by 33 · see citing works
Self-citationOxytocin and Facial Emotion Recognition
Ellenbogen, M. A. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_20 · Cited by 33 · see citing works
Abu-Akel, A. M., Fischer-Shofty, M., Levkovitz, Y., Jean Decety, A., & Shamay‐Tsoory, S. (2014) · Psychological Medicine · doi:10.1017/s003329171400097x · Cited by 33 · see citing works
Schwartz, S. S., Gallagher, R. J., & Berkson, G. (1986) · PubMed · Cited by 32 · see citing works
Brambilla, M., Cotelli, M., Manenti, R., Dagani, J., Sisti, D., Rocchi, M., Balestrieri, M., Pini, S., Raimondi, S., Saviotti, F. M., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.001 · Cited by 31 · see citing works
Patin, A., & Hurlemann, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_10 · Cited by 32 · see citing works
Realising stratified psychiatry using multidimensional signatures and trajectories
Joyce, D. W., Kehagia, A. A., Tracy, D. K., Proctor, J., & Shergill, S. S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1116-1 · Cited by 31 · see citing works
Coster, L. D., Lin, L. D., Mathalon, D. H., & Woolley, J. D. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0417-5 · Cited by 28 · see citing works
Razo, R. A., Berger, T., Conley, A. J., Freeman, S. M., Goetze, L. R., Jacob, S., Lawrence, R. H., Mendoza, S. P., Rothwell, E. S., Savidge, L. E., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104494 · Cited by 28 · see citing works
Role of Oxytocin in Different Neuropsychiatric, Neurodegenerative, and Neurodevelopmental Disorders
Ghazy, A. A., Soliman, O., Elbahnasi, A. I., Alawy, A. Y., Mansour, A. M., & Gowayed, M. A. (2022) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2022_72 · Cited by 27 · see citing works
Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats
Roberts, B. Z., Young, J. W., He, Y. V., Cope, Z. A., Shilling, P. D., & Feifel, D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.028 · Cited by 24 · see citing works
Oxytocin and interpersonal relationships
Patin, A., Scheele, D., & Hurlemann, R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_22 · Cited by 32 · see citing works
Strauss, G. P., Granholm, E. L., Holden, J. L., Ruiz, I., Gold, J. M., Kelly, D. L., & Buchanan, R. W. (2018) · Psychological Medicine · doi:10.1017/s0033291718002465 · Cited by 25 · see citing works
Buchanan, R. W., Kelly, D. L., Strauss, G. P., Gold, J. M., Weiner, E., Zaranski, J., Chen, S., Blatt, F., Holden, J. L., & Granholm, E. L. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001397 · Cited by 25 · see citing works
Social cognition across the schizophrenia–bipolar disorder spectrum
Lewandowski, K. E., Pinkham, A. E., & Rheenen, T. E. V. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-023-00269-7 · Cited by 22 · see citing works
Oxytocin and Social Cognitions in Schizophrenia: A Systematic Review
Bukovskaya, O., & Shmukler, A. B. (2015) · Psychiatric Quarterly · doi:10.1007/s11126-015-9407-x · Cited by 22 · see citing works
Socio-neuro risk factors for suicidal behavior in criminal offenders with psychotic disorders
Harenski, C. L., Brook, M. A., Kosson, D. S., Bustillo, J., Harenski, K. A., Caldwell, M. F., Rybroek, G. J. V., Koenigs, M. R., Jean Decety, A., Thornton, D. M., et al. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsw164 · Cited by 22 · see citing works
Balıkçı, K., Aydın, O., Taş, C., & Danacı, A. E. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1387405 · Cited by 17 · see citing works
Romero‐Martínez, Á., Sarrate‐Costa, C., & Moya‐Albiol, L. (2021) · Biology · doi:10.3390/biology10121334 · Cited by 18 · see citing works
Cowan, T., Strauss, G. P., Raugh, I. M., Le, T. P., & Cohen, A. S. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.03.024 · Cited by 17 · see citing works
Goh, K. K., & Lu, M. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.013 · Cited by 16 · see citing works
Marazziti, D., Diep, P.-T., Carter, C. S., & Carbone, M. G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220727120646 · Cited by 16 · see citing works
Quisenaerts, C., Morrens, M., Hulstijn, W., de Boer, P., Timmers, M., Sabbe, B., & de Bruijn, E. R. A. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00197 · Cited by 15 · see citing works
Pharmacological Treatment for Social Cognition: Current Evidence
Riccardi, C., Montemagni, C., Favero, E. D., Bellino, S., Brasso, C., & Rocca, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147457 · Cited by 15 · see citing works
Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders
Grove, T. B., Burghardt, K. J., Kraal, A. Z., Dougherty, R. J., Taylor, S. F., & Ellingrod, V. L. (2016) · Complex Psychiatry · doi:10.1159/000448173 · Cited by 15 · see citing works
The Causal Role of Temporoparietal Junction in Mediating Self–Other Mergence during Mentalizing
Sun, F., Yang, T., Liu, N., & Wan, X. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1026-23.2023 · Cited by 15 · see citing works
Tseng, H. C., Chi, M. H., Lee, L.-T., Tsai, H. C., Lee, I. H., Chen, K. C., Yang, Y. K., & Chen, P. S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.12.011 · Cited by 14 · see citing works
Hellemann, G., Green, M. F., Kern, R. S., Sitarenios, G., & Nuechterlein, K. H. (2017) · Psychological Medicine · doi:10.1017/s0033291717001052 · Cited by 14 · see citing works
Self-citationWigton, R. L., Tracy, D. K., Verneuil, T., Johns, M., White, T. P., Michalopoulou, P. G., Averbeck, B. B., & Shergill, S. S. (2021) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2021.100221 · Cited by 14 · see citing works
Lee, M. R., Wehring, H. J., McMahon, R., Liu, F., Linthicum, J., Buchanan, R., Strauss, G., Rubin, L., & Kelly, D. (2019) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20190001 · Cited by 13 · see citing works
Quintana, D. S. (2018) · OSF Preprints (OSF Preprints) · Cited by 12 · see citing works
Cella, M., Sedgwick, O., Lawrence, M., Grant, N., Tsapekos, D., Harrison, L., & Wykes, T. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114963 · Cited by 11 · see citing works
International perspective on social cognition in schizophrenia: current stage and the next steps
Corbera, S., Kurtz, M. M., Achim, A. M., Agostoni, G., Amado, I., Assaf, M., Barlati, S., Bechi, M., Cavallaro, R., Ikezawa, S., et al. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1776 · Cited by 13 · see citing works
Exploring a Possible Interplay between Schizophrenia, Oxytocin, and Estrogens: A Narrative Review
Papadea, D., Dalla, C., & Tata, D. Α. (2023) · Brain Sciences · doi:10.3390/brainsci13030461 · Cited by 11 · see citing works
Quintana, D. S., Rokicki, J., van der Meer, D., Alnæs, D., Kaufmann, T., Córdova‐Palomera, A., Dieset, I., Andreassen, O. A., & Westlye, L. T. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/149526 · Cited by 12 · see citing works
Campanale, A., Siniscalco, D., & Marzo, V. D. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01145-7 · Cited by 11 · see citing works
Trieu, M., Foster, A. E., Yaseen, Z. S., Beaubian, C., & Calati, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-29876-0_2 · Cited by 12 · see citing works
Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Arsenault‐Mehta, K., Hochman‐Bérard, M., Johnson, A., Semenova, D., Nguyen, B., Willis, J. V., Mouravska, N., Joober, R., & Zhand, N. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12382 · Cited by 8 · see citing works
The Use of Oxytocin in Personality Disorders: Rationale and Current Status
Pérez-Rodríguez, M. M., Derish, N. E., & New, A. S. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0026-1 · Cited by 7 · see citing works
Going From Social Neuroscience to Schizophrenia Clinical Trials
Green, M. F., & Penn, D. L. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt128 · Cited by 8 · see citing works
Self-citationLeng, G., & Ludwig, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.022 · Cited by 8 · see citing works
The Effects of Augmenting Clozapine with Oxytocin in Schizophrenia: An Initial Case Series
Marotta, R. F., Buono, F. D., Garakani, A., Collins, E. D., Cerrito, B., & Rowe, D. (2020) · Annals of Clinical Psychiatry · doi:10.1177/104012372003200211 · Cited by 7 · see citing works
Zhao, W., Zhang, X., & Kendrick, K. M. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106624 · Cited by 7 · see citing works
Loubat, O. M., & Astudillo-Zúñiga, A. (2019) · Terapia psicológica · doi:10.4067/s0718-48082019000300295 · Cited by 6 · see citing works
- Authors
- Davis, M. C., Lee, J., Horan, W. P., Clarke, A. D., McGee, M. R., Green, M. F., & Marder, S. R.
- Affiliations
- University of California, Los Angeles (US)
- Mental Illness Research, Education and Clinical Centers (US)
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 147
- Issue
- 2-3
- Pages
- 393-397
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2156784242
- Semantic Scholar
- d1ad461fe2ca502ac557d8923274b6ca9c690779
- Cited by
- 124
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 3 · 2019: 12 · 2018: 7 · 2017: 17 · 2016: 14 · 2015: 19 · 2014: 18 · 2013: 8
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Sensory Systems › Olfactory and Sensory Function Studies
- Keywords
- intranasal oxytocin, schizophrenia
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Cognition, Double-Blind Method, Empathy, Humans, Male, Middle Aged, Neuropsychological Tests, Oxytocin, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Social Behavior, Social Perception, Young Adult, Theory of Mind
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
